“…The subtype A strains included the prototype laboratory strains A2 and Long, the strain CH287 which was evaluated as a parenterally administered live vaccine (Belshe et al, 1982), the strains WV9894 and WV12138 characterized in a previous study (Mufson et al, 1985) and three strains (V214, V316, V401) isolated in Bristol, U.K. between 1983 and 1984 and provided by Dr E. J. Stott, Institute for Research on Animal Diseases, Compton, Newbury, U.K. The subtype B strains included two strains isolated during the early 1960s, CH18537 (Coates et al, 1963) obtained from Dr R. M. Chanock, NIAID, National Institutes of Health, Bethesda, Md., U.S.A. and a Swedish strain, 8/60 (Doggett & Taylor-Robinson, 1964), obtained from Dr E. J. Stott (both have been defined as B subtypes; E. Norrby, unpublished), the strains WV1293, WV3212, WV4843 and WV6873 characterized previously (Mufson et al, 1985) and two strains (V422 and V463) isolated in Bristol between 1983 and 1984 and provided by Dr E. J. Stott. The LEC strain of measles virus (see Sheshberadaran et al, 1983) was used as a control in experiments with tunicamycin-treated cells.…”